株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の次世代抗体治療市場の予測:2017年〜2027年

Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)

発行 Visiongain Ltd 商品コード 261354
出版日 ページ情報 英文 249 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=155.40円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の次世代抗体治療市場の予測:2017年〜2027年 Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)
出版日: 2017年05月25日 ページ情報: 英文 249 Pages
概要

世界の次世代抗体治療市場は、2016年の31億米ドルから、2021年には141億米ドルまで拡大すると見られています。市場は、2016年〜2027年のCAGR (複合年間成長率) で、22.4%の成長が予測されています。

当レポートでは、世界の次世代抗体治療市場について調査分析し、概要、世界/地域別市場、市場予測とパイプラインについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 次世代抗体治療とは

  • 抗体:概要
  • 次世代抗体の定義
  • 次世代抗体治療の分類
  • 次世代抗体技術の必要性
  • 次世代抗体の発展動向
  • 調査範囲
  • 治験の段階

第3章 次世代抗体治療:世界市場

  • 世界の次世代抗体治療市場の概要と区分
  • 主要な次世代抗体治療
  • 世界の次世代抗体治療市場:売上高予測
  • 区分別の市場シェアの変化予測
  • 世界の次世代抗体治療市場:促進要因・抑制要因

第4章 主要な地域市場

  • 世界の次世代抗体治療市場の地域内訳
  • 世界の次世代抗体治療市場:地域別の予測
  • 地域別の市場シェアの変化予測
  • 米国の次世代抗体治療市場
  • EU5ヶ国の次世代抗体治療市場
  • アジア太平洋地域の次世代抗体治療市場
  • ラテンアメリカの次世代抗体治療市場
  • その他の地域の次世代抗体治療市場

第5章 抗体薬物複合体 (ADC) :市場予測とパイプライン

  • 市場概要
  • 主なADC
  • ADC:市場予測
  • ADC市場:促進要因・抑制要因
  • Adcetris (brentuximab vedotin、Seattle Genetics/武田薬品工業)
  • Kadcyla (trastuzumab emtansine、Roche)
  • Mylotarg (gemtuzumab ozogamicin、Pfizer)
  • ADCのプラットフォーム
  • ADCは魅力的なハイバリュー取引
  • ADC:パイプライン分析
  • ADC:第3相パイプライン
  • ADC:第2相パイプライン
  • ADC:第1相パイプライン
  • ADC:前臨床パイプライン
  • ADC技術における将来の発展

第6章 改変抗体:市場予測とパイプライン

  • 「改変抗体」の定義
  • 市場概要、主要な改変抗体
  • 主要な改変抗体:市場予測
  • 改変抗体市場:促進要因・抑制要因
  • Poteligeo (mogamulizumab、協和発酵キリン)
  • Gazyva/Gazyvaro (obinutuzumab、Roche)
  • 改変抗体のプラットフォーム
  • 改変抗体:パイプライン分析
  • 改変抗体:第3相パイプライン
  • 改変抗体:第2相パイプライン
  • 改変抗体:第1相パイプライン

第7章 二重特異性抗体:市場予測とパイプライン

  • 二重特異性抗体:市場概要
  • 二重特異性抗体:市場予測
  • 二重特異性抗体市場:促進要因・抑制要因
  • Removab (catumaxomab、Neopharm)
  • Blincyto (blinatumomab、Amgen)
  • 二重特異性抗体のプラットフォーム
  • 二重特異性抗体:パイプライン分析
  • 二重特異性抗体:第1相・第1/2相・前臨床パイプライン

第8章 抗体フラグメント・抗体様タンパク質 (ALP) :市場予測とパイプライン

  • 抗体フラグメント・ALP:市場概要
  • 抗体フラグメント・ALP:市場予測
  • 抗体フラグメント・ALP:促進要因・抑制要因
  • Kalbitor (ecallantide、Shire)
  • 抗体フラグメント・ALPのプラットフォーム
  • 抗体フラグメント・ALP:パイプライン分析
  • 抗体フラグメント・ALP:第3相パイプライン
  • 抗体フラグメント・ALP:第2相パイプライン
  • 抗体フラグメント・ALP:第1相パイプライン

第9章 バイオシミラー抗体:市場予測

  • バイオシミラー抗体:市場概要
  • 主要なバイオシミラー抗体
  • バイオシミラー抗体:市場予測
  • バイオシミラー抗体市場:促進要因・抑制要因

第10章 次世代抗体治療市場の定性分析

  • 次世代抗体治療市場のSWOT分析
  • 次世代抗体治療市場のSTEP分析
  • 次世代抗体開発の主な目標

第11章 結論

第12章 用語集

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0195

The global next-generation antibody therapies market is expected to grow at a CAGR of 35.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 22.4% from 2016-2027. The market is estimated at $3.1bn in 2016 and $14.1bn in 2021.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 249-page report you will receive 133 charts - all unavailable elsewhere.

The 249-page report provides clear detailed insight into the global next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Next-Generation Antibody Therapies Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for next-generation antibody therapies, our investigation shows forecasts to 2027 for the following five submarkets:
    • Antibody-drug conjugates (ADCs)
    • Engineered antibodies
    • Bispecific antibodies
    • Antibody fragments and antibody-like proteins (ALPs)
    • Biosimilar antibody therapies
  • How will leading next-generation antibody therapies perform to 2027 at world level? Our study forecasts individual revenues of seven products:
    • Adcetris
    • Kadcyla
    • Gazyva/Gazyvaro
    • Poteligeo
    • Removab
    • Blincyto
    • Kalbitor
  • Our analyses show individual revenue forecasts to 2027 for these regional markets:
    • US
    • EU5 group
    • Asia-Pacific region
    • Latin America
    • Rest of the World
  • This report discusses issues affecting the next-generation antibody therapies market:
    • R&D for next generation antibodies
    • explore technologies and potentials
    • Challenges with current monoclonal antibody (mAb) therapies
    • Big pharma companies investing in next-generation antibody research and development
    • Biosimilars and their effects on the next-generation antibody therapies market
  • Our study discusses strengths, weaknesses, opportunities and threats as well as social, technological, economic and political factors that affect the next-generation antibody therapies market

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs).

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Next-Generation Antibody Therapies Overview
  • 1.2. Global Next-Generation Antibody Therapies Market Segmentation
  • 1.3. Why you Should Read this Report
  • 1.4. How this Report Delivers
  • 1.5. Main Questions Answered by This Analytical Study
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Introduction to Next-Generation Antibody Therapies

  • 2.1. Antibodies: An Overview
    • 2.1.1. Monoclonal versus Polyclonal Antibodies
    • 2.1.2. A Brief History of Antibody Drug Development
    • 2.1.3. The Antibody Manufacturing Process
    • 2.1.4. Trends in Antibody Development
  • 2.2. Defining Next-Generation Antibodies
  • 2.3. Classification of Next-Generation Antibody Therapies
  • 2.4. The Need for Next-Generation Technologies
  • 2.5. Development Trends for Next-Generation Antibodies
  • 2.6. Scope of this Report
  • 2.7. Phases of Clinical Trials

3. Next-Generation Antibody Therapies: World Market 2016-2027

  • 3.1. The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2016
  • 3.2. Leading Next-Generation Antibody Therapies
  • 3.3. World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2027
  • 3.4. How Will Segmental Market Shares Change to 2027?
  • 3.5. World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2027

4. Leading Regional Markets 2016-2027

  • 4.1. Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2016
  • 4.2. World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2027
  • 4.3. How Will Regional Market Shares Change to 2027?
  • 4.4. US Next-Generation Antibody Therapies Market 2016-2027
  • 4.5. EU5. Next-Generation Antibody Therapies Market 2016-2027
  • 4.6. Asia-Pacific Next-Generation Antibody Therapies Market 2016-2027
  • 4.7. Latin American Next-Generation Antibody Therapies Market 2016-2027
  • 4.8. The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2027

5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2027

  • 5.1. Market Overview, 2017
  • 5.2. Leading ADCs in 2017
  • 5.3. Antibody-Drug Conjugates: Market Forecast 2016-2027
  • 5.4. The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2027
    • 5.4.1. Novel Approaches Will Drive ADCs Market Growth
    • 5.4.2. Competition for Leading Drugs Will Restrain Growth
    • 5.4.3. Manufacturing ADCs Forms a Challenge
  • 5.5. Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
    • 5.5.1. Adcetris: Sales 2011-2016
    • 5.5.2. Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
    • 5.5.3. Expanding Adcetris Indications for Future Revenue Growth
    • 5.5.4. Adcetris Sales Forecast 2016-2027
  • 5.6. Kadcyla (trastuzumab emtansine, Roche)
    • 5.6.1. Mixed Results from Different Clinical Trials
    • 5.6.2. NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
    • 5.6.3. Kadcyla Sales Forecast 2016-2027
  • 5.7. Mylotarg (gemtuzumab ozogamicin, Pfizer)
    • 5.7.1. Mylotarg to be Relaunched?
  • 5.8. Antibody-Drug Conjugate Platforms
    • 5.8.1. Limited Market Opportunity for Radioconjugation
    • 5.8.2. Seattle Genetics' Platform Accounted for Over 40% of the Pipeline in 2016
    • 5.8.3. ImmunoGen: TAP Technology
    • 5.8.4. Immunomedics: Lower Potency Cytotoxics for Extended Use
    • 5.8.5. Preclinical Platforms for ADC Development
  • 5.9. ADCs Have Attracted High-Value Deals and will Continue to do so
  • 5.10. Antibody-Drug Conjugates: Pipeline Analysis 2016-2027
    • 5.10.1. The Longest Pipeline in the Next-Generation Antibodies Market
    • 5.10.2. Cancer Is the Only Target for Current Clinical-Stage ADCs
  • 5.11. Antibody-Drug Conjugates: Phase 3 Pipeline
    • 5.11.1. CMC544 (inotuzumab ozogamicin, Pfizer)
    • 5.11.2. Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
  • 5.12. Antibody-Drug Conjugates: Phase 2 Pipeline
    • 5.12.1. ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
    • 5.12.2. BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
    • 5.12.3. CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
    • 5.12.4. Immunomedics' IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
    • 5.12.5. MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
    • 5.12.6. MM-302 (anti-HER2, Merrimack Pharmaceuticals)
    • 5.12.7. PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
    • 5.12.8. SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
    • 5.12.9. Seattle Genetics' Phase 1 and Phase 2 ADCs
  • 5.13. Antibody-Drug Conjugates: Phase 1 Pipeline
  • 5.14. Antibody-Drug Conjugates: Preclinical Pipeline
  • 5.15. Future Developments in ADC Technology
    • 5.15.1. Site-Specific Linkage for Improved Safety Profiles

6. Engineered Antibodies: Market Forecast and Pipeline 2016-2027

  • 6.1. Defining an ‘Engineered Antibody'
  • 6.2. Market Overview 2017, and the Leading Engineered Antibodies
  • 6.3. Leading Engineered Antibodies: Market Forecast 2016-2027
  • 6.4. The Engineered Antibodies Market: Drivers and Restraints 2016-2027
  • 6.5. Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
    • 6.5.1. Poteligeo Sales Forecast 2016-2027
  • 6.6. Gazyva / Gazyvaro (obinutuzumab, Roche)
    • 6.6.1. Gazyva as a Challenger in the anti-CD20 Market
    • 6.6.2. Competition beyond Rituxan and Biosimilars
    • 6.6.3. Gazyva Receives Second Approval
    • 6.6.4. Gazyva Sales Forecast 2016-2027
  • 6.7. Engineered Antibodies Platforms
    • 6.7.1. Roche Glycart: GlucoMAb - Glycosylation for Improved ADCC
    • 6.7.2. Kyowa Hakko Kirin: Potelligent - Enhancing ADCC
    • 6.7.3. Glycotope: GlycoExpress
    • 6.7.4. MacroGenics: Fc Optimization
    • 6.7.5. Xencor: XmAb - Modifying Amino Acids in the Fc Domain
    • 6.7.6. Other Platforms for Increased Potency
  • 6.8. Engineered Antibodies: Pipeline Analysis 2016-2027
  • 6.9. Engineered Antibodies: Phase 3 Pipeline
    • 6.9.1. Benralizumab (MedImmune / Kyowa Hakko Kirin)
    • 6.9.2. Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
    • 6.9.3. MEDI4736 (anti-PDL1, AstraZeneca)
    • 6.9.4. RG7446/MPDL3280A (anti-PDL1, Roche)
    • 6.9.5. Ublituximab (anti-CD20, TG Therapeutics)
  • 6.10. Engineered Antibodies: Phase 2 Pipeline
    • 6.10.1. Glycotope's CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
    • 6.10.2. Margetuximab (anti-HER2, MacroGenics)
    • 6.10.3. MEDI-551 (anti-CD19, AstraZeneca)
    • 6.10.4. MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
    • 6.10.5. Teplizumab (anti-CD3, MacroGenics)
    • 6.10.6. BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
    • 6.10.7. XmAb5871 (anti-CD19, Xencor)
  • 6.11. Engineered Antibodies: Phase 1 Pipeline

7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2027

  • 7.1. Bispecific Antibodies: Market Overview, 2017
  • 7.2. Bispecific Antibodies: Market Forecast 2016-2027
  • 7.3. The Bispecific Antibodies Market: Drivers and Restraints 2016-2027
  • 7.4. Removab (catumaxomab, Neopharm)
    • 7.4.1. Removab: Sales Forecast 2016-2027
  • 7.5. Blincyto (blinatumomab, Amgen)
    • 7.5.1. Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
    • 7.5.2. Blincyto: Sales Forecast 2016-2027
  • 7.6. Bispecific Antibodies Platforms
    • 7.6.1. BiTE Platform: The Current Market Leader
    • 7.6.2. MacroGenics' DART Platform Holds Promise
    • 7.6.3. TriomAbs (TRION Pharma): Limited Market Impact 2016-2027
    • 7.6.4. Other Bispecific Antibody Platforms
  • 7.7. Bispecific Antibodies: Pipeline Analysis 2016-2027
    • 7.7.1. Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
    • 7.7.2. ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
    • 7.7.3. AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
    • 7.7.4. MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
    • 7.7.5. MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
    • 7.7.6. SAR156597 (anti-IL-4 and IL-13, Sanofi)
    • 7.7.7. Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
  • 7.8. Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline

8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2027

  • 8.1. Antibody Fragments and ALPs: Market Overview, 2017
  • 8.2. Antibody Fragments and ALPs: Market Forecast 2016-2027
  • 8.3. The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2027
  • 8.4. Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
    • 8.4.1. Kalbitor: Sales Forecast 2016-2027
  • 8.5. Antibody Fragments and ALPs Platforms
    • 8.5.1. Single-chain Variable Fragment Platforms
    • 8.5.2. Non-Antibody Protein Scaffolds: Antibody-Like Proteins
    • 8.5.3. Which Platform Will Lead the Market 2016-2027?
  • 8.6. Antibody Fragments and ALPs: Pipeline Analysis 2016-2027
    • 8.6.1. Ablynx Leads the Pipeline with Six Clinical Projects
  • 8.7. Antibody Fragments and ALPs: Phase 3 Pipeline
    • 8.7.1. Caplacizumab (anti-vWF, Ablynx)
    • 8.7.2. Abicipar (anti-VEGF, Allergan/Molecular Partners)
  • 8.8. Antibody Fragments and ALPs: Phase 2 Pipeline
    • 8.8.1. ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
    • 8.8.2. Ozoralizumab (anti-TNFα, Ablynx )
    • 8.8.3. DLX105 (anti-TNF-α, Delenex Therapeutics)
    • 8.8.4. ESBA1008 (anti-VEGF, Novartis)
  • 8.9. Antibody Fragments and ALPs: Phase 1 Pipeline
    • 8.9.1. ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
    • 8.9.2. ALX-0171 (anti-respiratory syncytial virus)
    • 8.9.3. ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
    • 8.9.4. Other Phase 1 Candidates, and the Preclinical Pipeline

9. Biosimilar Antibodies: Market Forecast 2016-2027

  • 9.1. Biosimilar Antibodies: Market Overview, 2017
  • 9.2. Leading Biosimilar Antibodies in 2016.
  • 9.3. Biosimilar Antibodies: Market Forecast 2016-2027
  • 9.4. The Biosimilar Antibodies Market: Drivers and Restraints 2016-2027
    • 9.4.1. New Launches of Biosimilar mAbs in Developed and Emerging Markets
    • 9.4.2. Rising Incidence of Cancer will Drive Demand
    • 9.4.3. Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
    • 9.4.4. Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2027

  • 10.1. SWOT Analysis of the Next-Generation Antibody Therapies Market
    • 10.1.1. Strengths: The Path Towards Market Acceptance
    • 10.1.2. Weaknesses: Multiple Companies Targeting Similar Indications
    • 10.1.3. Opportunities: Novel Platforms
    • 10.1.4. Threats: Entry of Biosimilars
  • 10.2. STEP Analysis of the Next-Generation Antibody Therapies Market
    • 10.2.1. Social Factors: Rising Demand for Cancer Therapies
    • 10.2.2. Technological Developments Will Drive Pipeline Growth
    • 10.2.3. Economic Pressures
    • 10.2.4. Political and Regulatory Issues
  • 10.3. Key Targets for Next-Generation Antibody Development 2016-2027
    • 10.3.1. Oncology Is the Lead Indication in All Sectors

11. Conclusions

  • 11.1. High Growth Potential in the Next-Generation Antibody Therapies Market in 2016-2027
  • 11.2. Current Status of the Market and Leading Segments
  • 11.3. Leading Next-Generation Antibody Therapies Profiled in this Report
  • 11.4. Leading Regional Markets
  • 11.5. Development of the Market to 2027
  • 11.6. Technology Platforms Will Continue to Attract Big Pharma Interest
  • 11.7. Most Developers Continue to Target Cancer
  • 11.8. Strategies for Growth in 2016-2027

12. Glossary

  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 (Sample) World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016-2021
  • Table 2.1 Monoclonal Antibody Types and Sources, 2017
  • Table 2.2 The Different Phases of Clinical Trials and What They Assess
  • Table 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2016
  • Table 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2016-2021
  • Table 3.3 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2022-2027
  • Table 3.4 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2027
  • Table 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2016
  • Table 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2016-2021
  • Table 4.3 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) by Region, 2022-2027
  • Table 4.4 Revenue ($m) and Market Shares (%) of Leading Regional Next-Generation Antibody Therapies Markets, 2027
  • Table 4.5 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.6 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.7 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.8 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.9 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.10 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.11 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.12 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 4.13 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2016-2021
  • Table 4.14 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), Global Market Share (%) 2022-2027
  • Table 5.1 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2016-2021
  • Table 5.2 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2022-2027
  • Table 5.3 Seattle Genetics: Adcetris Revenue ($m), 2011-2016
  • Table 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m), 2013-2016
  • Table 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 5.6 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 5.7 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 5.8 Kadcyla Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 5.9 ADC Pipeline by Platform and Phase, 2016
  • Table 5.10 Selected Preclinical ADC Development Platforms, 2016
  • Table 5.11 ADC Pipeline by Indication and Phase, 2016
  • Table 5.12 ADC Pipeline by Indication and Phase 3, 2016
  • Table 5.13 Selected Ongoing Clinical Trials for CMC544 (inotuzumab ozogamicin), 2016
  • Table 5.14 Roche's Antibody-Drug Conjugates Pipeline, 2016
  • Table 5.15 Ongoing Clinical Trials for RG7596 (polatuzumab vedotin), 2016
  • Table 5.16 Antibody-Drug Conjugates: Phase 2 Pipeline, 2016
  • Table 5.17 Ongoing Clinical Trials for ABT-414, 2016
  • Table 5.18 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 1, 2015 and 2016
  • Table 5.19 Antibody-Drug Conjugates: Phase 1 Pipeline, Table 2, 2016
  • Table 5.20 Antibody-Drug Conjugates: Preclinical Pipeline, 2016
  • Table 6.1 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 6.2 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027
  • Table 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 6.4 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 6.5 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 6.6 Total Gazyva Revenue Forecast (Roche): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 6.7 Engineered Antibodies Pipeline by Company and Phase, 2016
  • Table 6.8 Selected Licensing Agreements for the Potelligent Platform and Cell Lines, 2008-2015
  • Table 6.9 Engineered Antibodies Pipeline by Indication and Phase, 2016
  • Table 6.10 Engineered Antibodies: Phase 3 Pipeline, 2016
  • Table 6.11 Engineered Antibodies: Phase 2 Pipeline, 2016
  • Table 6.12 Margetuximab Recent and Ongoing Clinical Trials, 2016
  • Table 6.13 MEDI-551 Recent and Ongoing Clinical Trials, 2016
  • Table 6.14 Engineered Antibodies: Phase 1 Pipeline, 2016
  • Table 7.1 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.2 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027
  • Table 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.4 Removab (Neopharm) Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.5 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 7.6 Blincyto Revenue Forecast (Amgen): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 7.7 Bispecific Antibodies Pipeline by Company and Phase, 2016
  • Table 7.8 Selected Preclinical Bispecific Antibody Platforms, 2016
  • Table 7.9 Bispecific Antibodies Pipeline by Indication and Phase, 2016
  • Table 7.10 Bispecific Antibodies Pipeline by Indication and Phase, 2016
  • Table 7.11 Bispecific Antibodies: Phase 1/2 Pipeline, 2016, Table 1
  • Table 7.12 Bispecific Antibodies: Phase 1 Pipeline, 2016, Table 2
  • Table 7.13 Bispecific Antibodies: Preclinical Pipeline, 2016
  • Table 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 8.2 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2022-2027
  • Table 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2016-2021
  • Table 8.4 Kalbitor Revenue Forecast (Shire): Revenue ($m), AGR (%), CAGR (%), 2022-2027
  • Table 8.5 Ablynx: Selected Big Pharma Collaboration Agreements, 2012-2015
  • Table 8.6 Antibody Fragments and ALPs Pipeline by Company and Phase, 2016
  • Table 8.7 Antibody Fragments and ALPs Pipeline by Indication and Phase, 2016
  • Table 8.8 Antibody Fragments and ALPs: Phase 1 Pipeline, 2016
  • Table 8.9 Antibody Fragments and ALPs: Preclinical Pipeline, 2016
  • Table 9.1 Top Ten Best-Selling Drugs of 2014 (Within the Overall Pharmaceutical Market): Revenues ($bn), Market Shares (%)
  • Table 9.2 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 9.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 9.4 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 9.5 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 9.6 Patent Status of Five Leading mAbs, 2016
  • Table 10.1 Next-Generation Antibody Therapies Market: STEP Analysis, 2016-2027
  • Table 10.2 Selected CMOs Investing in Next-Generation Antibody Technologies, 2005-2015
  • Table 10.3 HER2 and HER3-Targeting Next-Generation Antibodies: Pipeline, 2016
  • Table 10.4 CD19 and CD20-Targeting Next-Generation Antibodies: Pipeline, 2016

List of Figures

  • Figure 1.1 Global Next-Generation Antibody Therapies Market Segmentation Overview, 2017
  • Figure 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2016
  • Figure 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%) by Segment, 2016-2027
  • Figure 3.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Segment, 2027
  • Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2016-2027
  • Figure 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) by Region, 2016
  • Figure 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) by Region, 2016-2027
  • Figure 4.3 World Next-Generation Antibody Therapies Market: Revenue ($m) by Region, 2027
  • Figure 4.4 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.5 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.6 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.7 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.8 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.1 ADC Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.2 ADC Market: Drivers and Restraints, 2016-2027
  • Figure 5.3 Seattle Genetics: Adcetris Revenue ($m) and AGR (%), 2011-2016
  • Figure 5.4 Total Adcetris Revenue (Seattle Genetics and Takeda): Revenue ($m) and AGR (%), 2013-2016
  • Figure 5.5 Total Adcetris Revenue Forecast (Seattle Genetics and Takeda): Revenue ($m) and AGR (%), 2016-2027
  • Figure 5.6 Kadcyla Revenue Forecast (Roche): Revenue ($m), 2016-2027
  • Figure 5.7 ADC Pipeline by Platform, 2016
  • Figure 5.8 ADC Pipeline by Phase, 2016
  • Figure 5.9 ADC Pipeline by Indication, 2016
  • Figure 6.1 Engineered Antibodies Market Forecast: Revenues ($m), 2016-2027
  • Figure 6.2 Engineered Antibodies Market: Drivers and Restraints, 2016-2027
  • Figure 6.3 Total Poteligeo Revenue Forecast (Kyowa Hakko Kirin): Revenue ($m), 2016-2027
  • Figure 6.4 Total Gazyva Revenue Forecast (Roche): Revenue ($m), 2016-2027
  • Figure 6.5 Engineered Antibodies Pipeline by Company, 2016
  • Figure 6.6 Engineered Antibodies Pipeline by Indication, 2016
  • Figure 6.7 Engineered Antibodies Pipeline by Phase, 2016
  • Figure 7.1 Bispecific Antibodies Market: Drivers and Restraints, 2016-2027
  • Figure 7.2 Bispecific Antibodies Market Forecast: Revenue ($m), 2016-2027
  • Figure 7.3 Removab (Neopharm) Revenue Forecast: Revenue ($m), 2016-2027
  • Figure 7.4 Blincyto Revenue Forecast (Amgen): Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.5 Bispecific Antibodies Pipeline by Company, 2016
  • Figure 7.6 Bispecific Antibodies Pipeline by Indication, 2016
  • Figure 7.7 Bispecific Antibodies Pipeline by Phase, 2016
  • Figure 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), 2016-2027
  • Figure 8.2 Antibody Fragments and ALPs Market: Drivers and Restraints, 2016-2027
  • Figure 8.3 Kalbitor Revenue Forecast (Shire): Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.4 Antibody Fragments and ALPs Pipeline by Company, 2016
  • Figure 8.5 Antibody Fragments and ALPs Pipeline by Indication, 2016
  • Figure 8.6 Antibody Fragments and ALPs Pipeline by Phase, 2016
  • Figure 9.1 Biosimilar Monoclonal Antibody Market Forecast, Split by Product: Revenue ($bn), 2016-2027
  • Figure 9.2 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($bn) and AGR(%), 2016-2027
  • Figure 10.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2016-2027
  • Figure 10.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2016-2026

Companies Listed

  • AbbVie
  • Ablynx
  • AdAlta
  • ADC Therapeutics
  • Affimed Therapeutics
  • Agensys
  • Alcon
  • Alexion
  • Allergan
  • Ambrx
  • Amgen
  • arGEN-X
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biogen Idec
  • BioNet Ventures
  • Biotest
  • BioWa
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cancer Drugs Fund
  • Catalent Pharma Solutions
  • Celgene
  • Celldex Therapeutics
  • Cephalon
  • Cilag GmbH International
  • Coldstream Laboratories
  • Concortis Biosystems
  • Corixa
  • Covagen
  • Crescendo Biologics
  • CSL Behring
  • CVie Therapeutics
  • Daiichi Sankyo
  • Defiante Farmaceutica
  • Delenex Therapeutics
  • Domantis
  • Dutalys
  • Dyax
  • Eddingpharm
  • Eisai
  • Eli Lilly
  • ESBATech
  • FDA
  • Five Prime Therapeutics
  • Fresenius Biotech
  • F-Star
  • Fujifilm
  • Genentech
  • Genmab
  • Gilead Sciences
  • Glenmark
  • Glycotope
  • Goodwin Biotechnology
  • GSK
  • Igenica
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • Janssen Biotech
  • Kalobios
  • Karolinska Institute
  • Kyowa Hakko Kirin
  • Kyowa Medex
  • LINDIS Biotech
  • Lonza
  • MacroGenics
  • MedImmune
  • Merck
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Micromet
  • Millennium Pharmaceuticals
  • Molecular Partners
  • MorphoSys
  • MultiCell Immunotherapeutics (MCIT)
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Neopharm
  • Neovii Biotech
  • NHS
  • NICE
  • Novartis
  • Novartis Institutes for BioMedical Research (NIBR)
  • NovImmune
  • Oxford BioTherapeutics
  • Oxis
  • Pfizer
  • Pharmacyclics
  • Piramal Healthcare
  • Pieris
  • Piramal Enterprises
  • PolyTherics
  • Progenics
  • ProStrakan
  • Redwood BioScience
  • Roche
  • Salix
  • Sanofi
  • Scil Proteins
  • Seattle Genetics
  • Servier
  • Shinogi
  • Shire
  • Sigma-Tau
  • Sorrento Therapeutics
  • Spectrum Pharmaceuticals
  • Spirogen
  • Stelis Biopharma
  • Strides Arcolab
  • Sutro Biopharma
  • Swedish Orphan Biovitrum (Sobi)
  • Swiss Federal Institute of Technology
  • Synthon
  • Takeda
  • Talon Therapeutics
  • Teva
  • TG Therapeutics
  • The American Society of Hematology
  • TRION Pharma
  • UCB
  • WHO
  • Wyeth
  • Xencor
  • Zydus Cadila
Back to Top